0001209191-19-019524.txt : 20190314 0001209191-19-019524.hdr.sgml : 20190314 20190314175107 ACCESSION NUMBER: 0001209191-19-019524 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190312 FILED AS OF DATE: 20190314 DATE AS OF CHANGE: 20190314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tilton John CENTRAL INDEX KEY: 0001704251 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38080 FILM NUMBER: 19682163 MAIL ADDRESS: STREET 1: C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP STREET 2: 234 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-12 0 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001704251 Tilton John C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN CT 06510 0 1 0 0 Chief Commercial Officer Common Shares 2019-03-12 4 M 0 10000 9.29 A 10000 D Common Shares 2019-03-12 4 S 0 10000 50.11 D 0 D Common Shares 1614 I By JET Ventures LLC Employee Stock Option (Right to Buy) 9.29 2019-03-12 4 M 0 10000 0.00 D 2027-01-30 Common Shares 10000 78792 D The exercise and sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 - $50.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The shares underlying this option vested as to 50% of the shares on January 31, 2017, with the remainder vesting in 2 equal installments on the first and second anniversaries of the grant date. /s/ Darren DeStefano, Attorney-in-Fact 2019-01-14